Has a wanted fugitive been posing as a biotech executive? And what does it take to develop a therapy for an ultra-rare ...

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people ...

Lilly's purchase of AtaiBeckley is yet another strategic move in its bid to diversify its pipeline.

American Airlines said it is on course for an adjusted loss in the current quarter after the latest surge in jet fuel prices. Comcast Reports Lower Profit, Narrows Domestic Broadband-Subscriber Losses ...

Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the company said, helping dispel lingering concerns over its potential as it ...

In recent days, Novo Nordisk filed a federal lawsuit against Eli Lilly, alleging that Lilly’s nationwide advertising for obesity and diabetes drugs like Zepbound and Mounjaro used outdated clinical ...

Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced it will release its second quarter 2026 financial and operating results on Thursday, August 6, 2026, following the close of ...

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.

A $2.5 billion settlement with Amazon Prime is in the works, a pharmaceutical company accuses another of false advertising ...

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of its obesity portfolio.

Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Comcast reported a lower profit in the second quarter, but narrowed subscriber losses in its domestic residential-broadband business for the second quarter in a row. Lockheed Martin Raises Full-Year ...